Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-21-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0001H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Whole blood

Sample Requirements

10 µl/well

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

12.5 – 0.39 amol/μl

Limit of Detection

0.13 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 7.0%

Inter-assay (Run-to-Run)

n = 5,
CV = 7.9%

Spiking Recovery

101.3%

Dilutation Linearity

99.2%

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-21-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Diabetology - Other Relevant Products, Oncology

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in the pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

hsa-miR-21-5p stands out as the most representative miRNA biomarker as it belongs to the first identified miRNA molecules. hsa-miR-21-5p is a circulating miRNA, strongly conserved through evolution, which has been extensively investigated in a range of studies of various diseases, such as cancer, cardiovascular disease, pulmonary diseases, regulation of immunological processes, and many others.

hsa-miR-21-5p was identified as a typical onco-miRNA. It modulates the expression of multiple cancer-related target genes and is dysregulated in various tumors. Besides tissues, recent evidence indicates the presence of miR-21-5p in various types of extracellular fluid, such as plasma, serum, CSF, saliva, gastric juice, pancreatic juice, sputum, and pancreatic cyst fluid. Up-regulated hsa-miR-21-5p could promote tumor growth, metastasis and invasion and reduce sensitivity to chemotherapy. The evidence from published meta-analyses revealed that high expression level of hsa-miR-21-5p was a negative predictor of survival in various cancers.
hsa-miR-21-5p is involved in many types of malignancies including brain cancer, lung cancer, colorectal cancer, pancreatic cancer, breast cancer, gastric cancer, esophageal cancer and hepatocellular carcinoma.

Besides altered expression of hsa-miR-21-5p in various malignancies, this miRNA is highly expressed in the cardiovascular system. Recent studies have revealed that its expression in the heart is dysregulated under cardiovascular disease conditions such as proliferative vascular disease, cardiac hypertrophy and heart failure or ischemic heart disease. hsa-miR-21-5p has been found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, calcific aortic valve disease and cardiac fibroblast functions.

References to Summary

References to miR-21-5p

  • Kao, H. W., et al. Urine miR-21-5p as a potential non-invasive biomarker for gastric cancer. Oncotarget (2017).
  • Shi, Rui, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget 6.29 (2015): 26971.
  • Peng, Qiliang, et al. The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Oncotarget 5 (2017).
  • Khalid, Usman, et al. MicroRNA‐21 (miR‐21) expression in hypothermic machine perfusate may be predictive of early outcomes in kidney transplantation. Clinical transplantation 30.2 (2016): 99-104.
  • Wang, Jialu, et al. Differential expression of circulating microRNAs in blood and haematoma samples from patients with intracerebral haemorrhage. Journal of International Medical Research 44.3 (2016): 419-432.
  • Parikh, Victoria N., et al. Brief Report: Coordinated Modulation of Circulating miR-21 in HIV, HIV-Associated Pulmonary Arterial Hypertension, and HIV/Hepatitis C Virus Coinfection. Journal of acquired immune deficiency syndromes (1999) 70.3 (2015): 236-241.
  • Elbehidy, Rabab M., et al. MicroRNA–21 as a novel biomarker in diagnosis and response to therapy in asthmatic children. Molecular immunology 71 (2016): 107-114.
  • Zhang, Y., et al. Plasma microRNA-21 is a potential diagnostic biomarker of acute myocardial infarction. Eur Rev Med Pharmacol Sci 20.2 (2016): 323-329.
  • Olivieri, Fabiola, et al. MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. Oncotarget 6.34 (2015): 35372.
  • Qu, Kai, et al. Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation. Scientific Reports 7 (2017).
  • Migita, Kiyoshi, et al. Circulating microRNA profiles in patients with type-1 autoimmune hepatitis. PloS one 10.11 (2015): e0136908.
Related Products Documents